In Vivo Toxicology Market Report 2026

In Vivo Toxicology Market Overview

• In Vivo Toxicology market size has reached to $5.61 billion in 2025 • Expected to grow to $7.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Rise In Drug Discoveries Fueling The Growth Of In Vivo Toxicology Due To Adoption Of Advanced Screening Technologies • Market Trend: Technological Advancements In Secure Data Systems To Enhance And Streamline Study Workflows • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under In Vivo Toxicology Market?

In vivo toxicology is a branch of toxicological science that involves studying the effects of chemical, biological, or physical agents on living organisms under controlled conditions. This approach focuses on observing how substances interact with complex biological systems, enabling the assessment of physiological, biochemical, and behavioral changes within an intact organism. The main products of in vivo toxicology include consumables and instruments. In vivo toxicology consumables are materials such as reagents, animal feed, and sample containers used during experiments conducted on live organisms to assess the safety or toxicity of substances. It offers various types of testing, such as chronic toxicity testing, sub-chronic toxicity testing, sub-acute toxicity testing, and acute toxicity testing, and uses several methodologies, including in vivo animal models, genetically modified organisms, non-human primate studies, rodent models, and larger mammals. It is applied for immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), and others by different end-users, including pharmaceutical companies, biosimilars manufacturers, contract research organizations (CROs), academic and research institutions, and biotechnology firms.

What Is The In Vivo Toxicology Market Growth Forecast?

The in vivo toxicology market size is expected to see strong growth in the next few years. It will grow to $7.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to development of genetically modified organisms for targeted studies, integration of automated and high-throughput screening systems, rising CRO outsourcing for toxicology testing, advancements in in vivo imaging and monitoring technologies, increasing focus on alternative models and reduction of animal testing. Major trends in the forecast period include growing adoption of rodent and non-human primate models, rising demand for advanced toxicology assay kits and reagents, expansion of immunotoxicity and genotoxicity testing services, increasing use of automated liquid handling and imaging systems, enhanced regulatory compliance and ethical standards in animal testing.

Global In Vivo Toxicology Market Segmentation

1) By Product: Consumables, Instruments 2) By Testing Types: Chronic Toxicity Testing, Sub-Chronic Toxicity Testing, Sub-Acute Toxicity Testing, Acute Toxicity Testing 3) By Methodology: In Vivo Animal Models, Genetically Modified Organisms, Non-Human Primate Studies, Rodent Models, Larger Mammals 4) By Application: Immunotoxicity, Systemic Toxicity, Carcinogenicity, Genotoxicity, Developmental And Reproductive Toxicity (DART), Other Applications 5) By End-User: Pharmaceutical Companies, Biosimilars Manufacturers, Contract Research Organizations (CROs), Academic And Research Institutions, Biotechnology Firms Subsegments: 1) By Consumables: Animal Models, Reagents And Kits, Assay Kits, Toxicology Testing Media, Antibodies, Biochemicals, Buffers And Solutions, Disposable Labware, Animal Feed, Diluents 2) By Instruments: Imaging Systems, Flow Cytometers, PCR Machines, Spectrophotometers, Microscopes, Analyzers, Centrifuges, Incubators, Animal Monitoring Systems, Automated Liquid Handling Systems

What Is The Driver Of The In Vivo Toxicology Market?

The increasing number of drug discoveries is expected to propel the growth of the in vivo toxicology market going forward. Drug discovery involves the scientific identification and design of new compounds that may serve as treatments or preventatives for various diseases. Progress in biotechnology has significantly boosted this process by enhancing the understanding of how diseases work and enabling the creation of more targeted therapies. In vivo toxicology is essential in drug discovery, enabling the evaluation of safety, tolerability, and potential adverse effects of investigational compounds in whole organisms. It helps identify dose-limiting toxicities and informs formulation and dosing strategies prior to clinical development. For instance, in November 2024, according to the Patented Medicine Prices Review Board (PMPRB), a Canada-based government agency, over 12,000 new medicines were in clinical trials in 2023, up from around 9,000 in 2022, with oncology accounting for 33% of the pipeline and infectious and central nervous system diseases representing 13% and 12%, respectively. Therefore, the increasing number of drug discoveries is driving the growth of the in vivo toxicology industry.

Key Players In The Global In Vivo Toxicology Market

Major companies operating in the in vivo toxicology market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (Labcorp), Sigma-Aldrich Co. LLC, Eurofins Scientific SE, Agilent Technologies Inc., WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Jubilant Life Sciences Limited, Evotec SE, The Jackson Laboratory, Inotiv Inc., Transcure Bioservices Pvt. Ltd.

Global In Vivo Toxicology Market Trends and Insights

Major companies operating in the in vivo toxicology market are focusing on developing advanced solutions, such as secure cloud-based real-time data platforms, to streamline study management and improve decision-making speed. Secure cloud-based real-time data platforms allow researchers and clients to access toxicology study data, milestones, planning tools, and documents remotely and securely, enhancing collaboration and transparency. For instance, in March 2023, Charles River Laboratories International Inc., a US-based contract research organization, launched Apollo, a secure cloud-based platform designed to provide real-time access to toxicology study data. It is a cloud-based, secure platform designed to support in vivo general toxicology studies with tools for data visualization, planning, and milestone tracking. It enables quicker and more informed decisions by providing real-time access to critical study data. The platform also helps streamline project planning and budget estimation throughout the drug development process. By digitizing toxicology workflows, Apollo enhances precision, efficiency, and collaboration in in vivo research.

What Are Latest Mergers And Acquisitions In The In Vivo Toxicology Market?

In October 2023, ETAP Lab SAS, a France based preclinical contract research organization (CRO), acquired Syncrosome SAS, a France based preclinical CRO specializing in in vivo pharmacology for cardio pulmonary pathologies. With this acquisition, ETAP Lab SAS aims to strengthen its cardiovascular and pulmonary disease model capabilities and expand its service portfolio. Syncrosome SAS is a France based CRO that provides in vivo R&D services in cardiology and pneumology.

Regional Insights

North America was the largest region in the in-vivo toxicology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the In Vivo Toxicology Market?

The in vivo toxicology market consists of revenues earned by entities by providing services such as neurotoxicity assessment, dermal toxicity testing, ocular toxicity testing, and local tolerance testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vivo toxicology market also includes sales of anesthesia systems, telemetry devices, blood collection and sampling tools, drug delivery systems, and environmental control equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the In Vivo Toxicology Market Report 2026?

The in vivo toxicology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the in vivo toxicology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.